Amyloid-beta (Aβ) deposition is associated with decreased dopamine transporter activity (DAT), younger age and higher cognitive and neuropsychiatric burden in patients with dementia with Lewy bodies (DLB), suggesting that evaluation of clinical features and DAT activity can predict the presence of Aβ in DLB.
Why this matters
Aβ deposition in DLB is associated with faster neurodegeneration and earlier onset of dementia. Recent evidence suggests that higher Aβ deposition in DLB is associated with faster or more extensive gray matter atrophy in the cortex and striatum. Identification of the predictors of Aβ pathology in DLB is necessary to improve patients’ quality of life and reduce caregiver burden.